A new trading day began on Friday, with Charles River Laboratories International Inc (NYSE: CRL) stock price down -0.83% from the previous day of trading, before settling in for the closing price of $169.21. CRL’s price has ranged from $91.86 to $208.10 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -47.65%. Meanwhile, its annual earnings per share averaged -0.84%. With a float of $48.64 million, this company’s outstanding shares have now reached $49.22 million.
Charles River Laboratories International Inc (CRL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Charles River Laboratories International Inc is 1.17%, while institutional ownership is 104.15%. The most recent insider transaction that took place on Aug 22 ’25, was worth 61,000. Before that another transaction happened on Aug 18 ’25, when Company’s EVP, Corp Strategy & Develop sold 800 for $157.60, making the entire transaction worth $126,080. This insider now owns 24,116 shares in total.
Charles River Laboratories International Inc (CRL) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of 2.66 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.85% during the next five years compared to -47.65% drop over the previous five years of trading.
Charles River Laboratories International Inc (NYSE: CRL) Trading Performance Indicators
Here are Charles River Laboratories International Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.05. Likewise, its price to free cash flow for the trailing twelve months is 15.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit 2.35 in the next quarter and is forecasted to reach 10.92 in one year’s time.
Technical Analysis of Charles River Laboratories International Inc (CRL)
Looking closely at Charles River Laboratories International Inc (NYSE: CRL), its last 5-days average volume was 1.24 million, which is a jump from its year-to-date volume of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 45.86%.
During the past 100 days, Charles River Laboratories International Inc’s (CRL) raw stochastic average was set at 42.51%, which indicates a significant increase from 23.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 6.66 in the past 14 days, which was higher than the 5.67 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $168.71, while its 200-day Moving Average is $155.01. However, in the short run, Charles River Laboratories International Inc’s stock first resistance to watch stands at $169.52. Second resistance stands at $171.24. The third major resistance level sits at $173.47. If the price goes on to break the first support level at $165.57, it is likely to go to the next support level at $163.34. Now, if the price goes above the second support level, the third support stands at $161.62.
Charles River Laboratories International Inc (NYSE: CRL) Key Stats
With a market capitalization of 8.26 billion, the company has a total of 49,215K Shares Outstanding. Currently, annual sales are 4,050 M while annual income is 22,200 K. The company’s previous quarter sales were 1,005 M while its latest quarter income was 54,420 K.
